The FDA approved the first DNA plasmid immunotherapy, pushing the number of new molecular entity approvals to 47 for the year as reported in a BIOCENTURY data byte. The approval marks a regulatory endorsement of a DNA-based immunotherapy modality that has historically faced translation and delivery challenges compared with viral vectors and mRNA platforms. For developers and investors, the milestone is less about a single product and more about platform credibility: it signals continued openness to alternative nucleic-acid formats provided that immunogenicity, safety, and manufacturing controls are robust. As the sector looks to immunotherapy diversification, this adds weight to investment in next-generation plasmid design, delivery systems, and trial strategies capable of demonstrating clinically meaningful outcomes in defined patient populations.